A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
The purpose of this study is to investigate and characterize the association of lenalidomide with tumor flare reaction and high tumor burden in participants with relapsed or refractory mantle cell lymphoma.
This is a European multinational, retrospective, non-interventional study of participants with relapsed or refractory mantle cell lymphoma (R/R MCL). Potential sites will be identified where R/R MCL participants have been treated with lenalidomide. Site inclusion will be limited to countries where lenalidomide is reimbursed for this indication.
Inclusion Criteria:
Received at least one dose of lenalidomide commencing after 08 July 2016 for the treatment of relapsed refractory mantle cell lymphoma.
Informed consent of the patient or an authorized third person or authority, if required by law, given prior to data collection.
Patient must be ≥18 years of age at the time of signing the informed consent form.
Exclusion Criteria:
1) Patients will be excluded if they were participating in an interventional clinical trial during the treatment period under observation in this Post Authorization Safety Study.
Salzburger, 5020, Austria
Paris, 75013, France
Saint Quentin Picardie, 2321, France
Frankfurt/ Oder Brandenburg, 15236, Germany
Alexandrouppoli, 68100, Greece
Athens Goudi, 11527, Greece
Piraeous, 18537, Greece
Rio, Patras, 265 04, Greece
Siena, 53100, Italy
Venezia - Mestre, 30174, Italy
The Hague, 2545 AA, Netherlands
Alava País Vasco, 1009, Spain